UNSPSC 51291510: Fezolamine

This classification denotes an antidepressant agent with the molecular formula C20H23N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 1133E05F6C chemically known as 1-(3-(dimethylamino)propyl)-3,4-diphenylpyrazole but generally known as fezolamine, which bears US NIH Compound Identifier 54567. European Medicines Agency schedules Fezolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07620MIG.

UNSPSC 51291510 Fezolamine is a Commodity code that in state and local procurement practice covers pharmaceutical products and drug-related supplies, though recent solicitation activity under this code shows misalignment with the nominal fezolamine scope. Seminole County, Florida posted a competitive IFB for naloxone and safe drug deactivation systems — a public health procurement supporting community health initiatives rather than a fezolamine-specific buy. The county solicited 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries. Bidders must submit electronically, include all shipping and delivery costs, hold drug-free workplace certification and E-Verify compliance, and maintain workers' compensation, commercial general liability, and professional liability insurance. The contract runs two years with an optional one-year renewal, includes a three-month probationary termination window, and is potentially FEMA-funded, bringing Clean Air Act and Federal Water Pollution Control Act compliance requirements into play.

Recent activity under this code shows limited visibility into active state and local procurement. The single documented opportunity — Seminole County IFB 60459723LAS, posted June 30, 2026, with a response deadline of July 26, 2023 — targets naloxone and drug deactivation systems rather than fezolamine products. Geographic activity appears concentrated in Florida based on available records, though the source does not support a broader characterization of issuing-body types or multi-state engagement under this code. The posted opportunity does not specify set-aside designations for small business, minority-owned, women-owned, or other disadvantaged-enterprise programs. Given the mismatch between the code's nominal pharmaceutical scope and the actual health-supply procurement documented, this code shows little relevant recent activity for vendors focused on fezolamine-specific opportunities.